Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EBOS Group Limited ( (AU:EBO) ) just unveiled an update.
EBOS Group Limited has announced the lapse of 29,742 performance rights (ASX code: EBOAA) after the conditions attached to those rights were not met or became incapable of being satisfied as of 5 January 2026. The cessation of these conditional securities effectively reduces the pool of potential future equity issuance under this particular incentive arrangement, with limited direct operational impact but some implications for the structure and value of outstanding executive or employee equity incentives.
The most recent analyst rating on (AU:EBO) stock is a Hold with a A$26.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited, listed on the ASX under the code EBO, operates in the healthcare and pharmaceutical distribution sector, supplying a broad range of healthcare products and services across Australia and New Zealand. The company plays a significant role in the regional healthcare supply chain, servicing pharmacies, hospitals, and other health providers.
Average Trading Volume: 120,357
Technical Sentiment Signal: Sell
Current Market Cap: A$4.88B
See more data about EBO stock on TipRanks’ Stock Analysis page.